Champions Oncology, Inc. (CSBR) has a negative trailing P/E of -36.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 47.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -2.76%, forward earnings yield 2.09%.
Criteria proven by this page:
Overall SharesGrow Score: 52/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.2 | 0.16 | 140.66 | 2.99 | - |
| 2017 | -4.1 | 0.09 | 70.25 | 1.82 | - |
| 2018 | -32.3 | 0.41 | 15,882.88 | 2.35 | - |
| 2019 | 804.4 | -7.40 | 46.01 | 3.80 | - |
| 2020 | -43.7 | 0.03 | 17.93 | 2.85 | - |
| 2021 | 389.5 | -3.38 | 18.98 | 3.44 | - |
| 2022 | 185.0 | 3.67 | 11.14 | 2.06 | - |
| 2023 | -12.3 | 0.01 | 14.20 | 1.22 | - |
| 2024 | -9.0 | -0.23 | -34.53 | 1.31 | - |
| 2025 | 20.8 | -0.13 | 25.89 | 1.72 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.20 | $11.18M | $-10.45M | -93.4% |
| 2017 | $-0.63 | $15.41M | $-6.88M | -44.7% |
| 2018 | $-0.14 | $20.24M | $-1.51M | -7.4% |
| 2019 | $0.01 | $27.07M | $128K | 0.5% |
| 2020 | $-0.17 | $32.12M | $-1.98M | -6.1% |
| 2021 | $0.02 | $41.04M | $362K | 0.9% |
| 2022 | $0.04 | $49.11M | $548K | 1.1% |
| 2023 | $-0.39 | $53.87M | $-5.34M | -9.9% |
| 2024 | $-0.54 | $50.16M | $-7.28M | -14.5% |
| 2025 | $0.33 | $56.94M | $4.7M | 8.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.12 | $0.12 – $0.12 | $58.53M | $58.53M – $58.53M | 1 |
| 2027 | $0.10 | $0.10 – $0.10 | $65.26M | $65.26M – $65.26M | 1 |
| 2028 | $0.00 | $0.00 – $0.00 | $70.81M | $70.81M – $70.81M | 0 |
